Stealth BioTherapeutics Corp.

09/07/2021 | Press release | Distributed by Public on 09/07/2021 14:33

Stealth BioTherapeutics to Present at Upcoming September Virtual Investor Conferences

BOSTON, Sept. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at two upcoming virtual investor conferences in September:

  • H.C. Wainwright 23rd Annual Global Investment Conference. Pre-recorded presentation available for on-demand viewing starting on Monday, September 13 at 7:00 a.m. ET.
  • Cantor Global Healthcare Conference. Fireside chat on Thursday, September 30 at 11:20 a.m. ET.

A live audio webcast of the presentations will be available on the Investors & News section of Stealth's website at https://investor.stealthbt.com/. A replay of the webcasts will be archived on Stealth's website for 30 days following the event.

About Stealth

We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth syndrome, Duchenne muscular dystrophy and Friedreich's ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.

Investor Relations
 Stern Investor Relations
Janhavi Mohite, 212-362-1200
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-at-upcoming-september-virtual-investor-conferences-301370687.html

SOURCE Stealth BioTherapeutics Inc.